Calgary, AB, Canada - December 13, 2010, Calgary, AB, Canada - Resverlogix Corp., a biotechnology company, announced that Eldon R. Smith has been appointed to the board of directors.
Article continues below
From 1992 to 1997, Dr. Smith was Dean of the Faculty of Medicine at the University of Calgary. From 1997 until 2010, he has been Editor-in-Chief of the Canadian Journal of Cardiology. Dr. Smith's research interests include circulatory mechanics, exercise physiology and echocardiography.
Dr. Smith has published more than 250 papers and book chapters and has been a contributor to many national and international organizations; he has been President of the Canadian Cardiovascular Society and the Association of Canadian Medical Colleges and Vice President of the Inter-American Society of Cardiology.
Dr. Smith has served on a number of public boards including the Alberta Heritage Foundation for Medical Research, the Alberta Health Professions Advisory Board, and the Premier's Advisory Council on Health in Alberta. He founded and served as President and Director of the Peter Lougheed Medical Research Foundation, a national initiative to support excellence in health research in Canada.
Dr. Smith is chair of the Advisory Board of the Libin Cardiovascular Institute of Alberta and from 2006 to 2010 he was appointed by the Federal Government to chair the development of a National Strategy for Cardiovascular Health and Disease.
The company also announced that William Cochrane will be stepping down from the board, effective immediately.
Dr. Cochrane's career has spanned the fields of medicine, biomedical research, education and business. He was the founding Dean of Medicine for the University of Calgary building a medical school from the ground up, instituting a new integrated and interdisciplinary approach to medical education that has since become the norm across Canada.
In 1978, Dr. Cochrane took his career in a new direction as Chairman and Chief Executive Officer of Connaught Laboratories. During his tenure with the company, Connaught became a major international developer of flu vaccines for the World Health Organization.
During his career, Dr. Cochrane has shared his leadership with a range of organizations, from the National Biotechnology Advisory Committee, the Alberta Research Council to private sector ventures and non-profit organizations. ■